139 related articles for article (PubMed ID: 8343260)
1. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
Cochran AJ; Buyse ME; Lejeune FJ; Macher E; Revuz J; Rümke P
Int J Cancer; 1981 Nov; 28(5):543-50. PubMed ID: 7309294
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
[TBL] [Abstract][Full Text] [Related]
7. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
Morton DL; Eilber FR; Holmes EC; Ramming KP
Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
[TBL] [Abstract][Full Text] [Related]
10. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
11. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
[TBL] [Abstract][Full Text] [Related]
13. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy of melanoma.
Agarwala SS; Kirkwood JM
Semin Surg Oncol; 1998 Jun; 14(4):302-10. PubMed ID: 9588723
[TBL] [Abstract][Full Text] [Related]
18. Surgical adjuvant therapy for malignant melanoma.
Pinsky CM; Oettgen HF
Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
[No Abstract] [Full Text] [Related]
19. [Immunotherapy of malignant melanoma].
Adler A
Harefuah; 1986 Jul; 111(1-2):11-7. PubMed ID: 3781371
[No Abstract] [Full Text] [Related]
20. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.
Quirt IC; Shelley WE; Pater JL; Bodurtha AJ; McCulloch PB; McPherson TA; Paterson AH; Prentice R; Silver HK; Willan AR
J Clin Oncol; 1991 May; 9(5):729-35. PubMed ID: 2016615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]